



**Danville Regional**  
MEDICAL CENTER

September 9, 2004

Ms Sandra Gabriel  
Senior Health Physicist  
Division of Nuclear Materials Safety  
Region 1  
475 Allendale Road  
King of Prussia, PA 19406

Dear Ms Gabriel;

I am submitting to you the follow up response of Dr Leider in reference to the potential medical event.

Should you have further questions or concerns, please contact me directly by calling 434-799-2375.

Sincerely,

Gerald Johnson Ph.D.  
Division Director

188 South Main Street  
Danville, VA 24541

Tel: 866-472-6636  
Fax: 434-799-4556

September 7, 2004

Nuclear Regulatory Commission

RE: Case which has been discussed this summer

A post implant CT scan approximately one month after the implant was performed on 8-27-04, the date of the implant being 7-15-04.

After contouring structures and reviewing dosimetry, it was apparent that out of 72 sources 41 of the sources appeared to be in the prostate gland, 30 of the sources outside of the prostate gland and one of the sources in the seminal vesicles.

The V 100 was 59.37% and the D 90 was 64.22% with a D 50 being 107.91%.

A Foley catheter was not inserted at the time of the post-implant CT scan and urethral dosimetry was not performed.

The rectum was contoured and none of the rectal doses appeared to be worrisome.

A significant number of the seeds outside of the gland are in the periprostatic soft tissues which due to difficulty in describing this as a target structure, was not described as a target structure. However, I would estimate that roughly 20 of the sources are outside of prostate gland, seminal vesicles and periprostatic soft tissues. These seeds outside the gland are mainly located inferior to the prostate gland in the pelvic floor musculature and in the upper most portion of the penis. I would not anticipate these sources or the radioactivity associated with them putting the patient at risk for significant short or late term morbidity.

I am not recommending any further treatment for the prostate cancer. He did receive a single Zoladex depot injection, per my recommendation, about four weeks ago, after I met with him in follow-up.



Peter J. Leider, M.D.

Southern Virginia Radiation Oncology, P.C.

PL/dd